Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells

Molecular Medicine Reports
Ming-Na LiuBing-Rong Liu

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. Chemotherapeutic compounds used for the treatment of CRC include oxaliplatin (L-OHP). While L-OHP improves CRC survival, certain patients are resistant. The nitrogen permease regulator like-2 (NPRL2) gene is a candidate tumor suppressor gene that resides in a 120-kb homozygous deletion region on chromosome 3p21.3. In the present study, it was demonstrated that NPRL2 overexpression increases the sensitivity of HCT116 cells to L-OHP. The IC50 of L-OHP was decreased in cells transduced with NPRL2 compared with negative control (NC) cells and the effect of NPRL2 on L-OHP sensitivity was time dependent. Following NPRL2 transduction in HCT116 cells, the cell cycle was arrested in the G1 phase and a partial decrease in the S phase population was observed. Flow cytometric analysis revealed that NPRL2 transduction and L-OHP treatment increased apoptosis compared with NC cells. The mechanism through which NPRL2 overexpression enhances L-OHP sensitivity involves downregulation of the functions of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin network. Furthermore, L-OHP upregulated caspase-3 and caspase-9 to promote apoptosis in NPRL2-overexpressing ce...Continue Reading

References

Jul 1, 1994·International Immunology·M SammarP Altevogt
Sep 16, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S AignerK Ley
Dec 2, 2000·Nature·B B Zhou, S J Elledge
Sep 17, 2005·Pathology, Research and Practice·Sung-Chul Lim, Seon-Hee Oh
May 13, 2006·Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews·Farid E Ahmed
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anthony D YangLee M Ellis
Aug 19, 2007·Cancer Research·Gemma ArmengolSantiago Ramón y Cajal
Oct 3, 2007·Annals of Surgical Oncology·Ami N ShahGary E Gallick
Jan 23, 2008·Expert Opinion on Therapeutic Targets·Sauveur-Michel MairaCarlos Garcia-Echeverria
Sep 17, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jenny N PoynterUNKNOWN Colon Cancer Family Registry
Feb 16, 2010·Nutrition and Cancer·Bhaumik B Patel, Adhip P N Majumdar
Apr 28, 2010·Gastroenterology·Andrew T Chan, Edward L Giovannucci
Apr 28, 2010·Journal of the American College of Surgeons·Sara M JohnsonB Mark Evers
Dec 16, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wolfgang GlienkeLothar Bergmann
Jul 31, 2012·BMC Gastroenterology·Ching-Shya YongChin-Cheng Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis